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Abstract
Amidst an ongoing opioid crisis that claimed 47,600 lives in 2017, increasing the availability of the rescue
medication naloxone is a high priority. Naloxone reverses an opioid overdose when given intranasally or
intramuscularly. But to be effective, naloxone must be available at the time of overdose. Naloxone distribution
to laypeople can save a life when first responders are not immediately available, or when people witnessing
overdoses are unwilling or unable to call 911. Naloxone is increasingly available through some pharmacies
under a standing order; however, even when available, cost and stigma barriers persist. This Issue Brief reviews
recent evidence on the outcomes and cost-effectiveness of naloxone distribution strategies in community,
pharmacy, and other health care settings.
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Amidst an ongoing opioid crisis that claimed 47,600 lives in 2017, increasing the availability 
of the rescue medication naloxone is a high priority. Naloxone reverses an opioid overdose 
when given intranasally or intramuscularly. But to be effective, naloxone must be available 
at the time of overdose.
The U.S. Department of Health and Human Services identifies naloxone distribution as one 
of the top three strategies for addressing the opioid epidemic. Last year, the U.S. Surgeon 
General called naloxone a “safe antidote” to a suspected overdose, and urged more  
individuals to carry naloxone, including family, friends, community members, and those 
who are personally at risk. 
Naloxone distribution to laypeople can save a life when first responders are not  
immediately available, or when people witnessing overdoses are unwilling or unable to call 
911. Naloxone is increasingly available through some pharmacies under a standing order; 
however, even when available, cost and stigma barriers persist. This Issue Brief reviews 
recent evidence on the outcomes and cost-effectiveness of naloxone distribution strategies 
in community, pharmacy, and other health care settings. 
Naloxone use and availability
Naloxone is currently available in three forms: injection formulations, auto-injectors, and 
nasal sprays. Despite the surge in deaths related to opioid overdoses, the market for  
naloxone remains small. One industry analyst estimated the entire naloxone market has 
about $290 million in annual sales. A recent analysis conducted for the Food and Drug  
Administration (FDA) estimated that national naloxone sales to all settings of care doubled 
from 2013 to 2017, with the majority being the injection formulation. About 83% of  
naloxone units were sold to non-retail settings of care, such as hospitals and clinics, health 
departments, and institutions that supply first responders, emergency medical services, 
and community groups. Seventeen percent of sales were to retail and mail-order/specialty 
pharmacies, up from 3% of total sales in 2013. The retail setting accounted for a small but 
growing proportion of total naloxone dispensing. The number of naloxone prescriptions 
filled at U.S. retail pharmacies more than doubled from 134,000 prescriptions in 2016 to 
330,000 prescriptions in 2017. More than 70% of the naloxone prescriptions filled in retail 
pharmacies in 2017 were for the nasal spray Narcan®, followed by 20% for the autoinjector 
Evzio®. This is not surprising given the differences in list price between the two products 
(about $150 per two pack of Narcan® and over $4,000 per two pack of Evzio®.) Injection 
formulations are much less expensive, but retail sales are dominated by the branded  
products specifically designed for bystander use.
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The potential need for naloxone is large, given that about 2.1 million people 12 and older in 
the U.S. have an opioid use disorder. Ultimately, the goal of naloxone distribution strategies 
is to make this life-saving medication available to people most likely to observe an  
opioid overdose, in time to reverse respiratory depression. These strategies must go beyond 
health care providers and health system settings, to reach people at risk, their social  
networks, and the communities in which they live. 
Community-based and pharmacy naloxone distribution
Naloxone is available to laypeople through two basic channels: as part of overdose  
education and naloxone distribution (OEND) programs for those at risk of overdose (and 
people in their social networks), and through pharmacies. A wide variety of organizations 
participate in OEND efforts, such as syringe exchange programs, homeless shelters,  
emergency medical services, social service agencies, libraries, emergency departments, 
health care providers, and substance use disorder treatment programs. Little is known 
about how well different types of OEND programs reach individuals most likely to witness 
an overdose, as well as the cost of providing services. Depending on state law, some  
pharmacies distribute naloxone through a standing order or through direct pharmacist  
prescribing. Pharmacy availability, consumer acceptance, and out-of-pocket costs vary 
across jurisdictions. The FDA is considering converting individual naloxone products to  
over-the-counter (OTC) status. 
Opioid Education and Naloxone Distribution (OEND) programs
Observational studies and economic models suggest that OEND programs prevent deaths 
and are cost-effective. Walley, Xuan, Hackman, et al. (2013) found that Massachusetts  
communities with an OEND had lower opioid overdose death rates than communities  
without an OEND. In that study, OEND programs trained 2,912 potential bystanders  
between 2006 and 2009, who reported 327 rescues. Bird, McAuley, Perry, & Hunter (2016) 
found that a national program in Scotland to distribute naloxone to people released from 
prison (a time of high risk for overdose) was associated with a 36% reduction in the  
proportion of opioid-related deaths that occurred in the four weeks following release from 
prison. In this pre-post study, the distribution of 12,000 naloxone kits was associated with 
42 fewer prison-release overdose deaths during 2011-13. A followup commentary by Bird 
and McAuley (2019) noted that by 2016, the goal of distributing 9,000 rescue kits (20 times 
Scotland’s average number of yearly opioid-related deaths) had been met, and such deaths 
in the four weeks after prison release had been halved since 2011.
Economic modelling studies find that OEND programs for people who use heroin are 
cost-effective, when using a standardized measure of the length of life adjusted for the 
quality of life (quality-adjusted life-years, or QALYs). Coffin & Sullivan (2013) estimated that 
6% of overdose deaths among heroin users could be prevented with distribution, or one 
death for every 277 naloxone kits distributed. Naloxone distribution increased costs by $53 
and produced a gain of 0.12 QALYs, for an incremental cost-effectiveness ratio of $438 per 
QALY gained. These results have been replicated in other studies of heroin users by Uyei 
et al. (2017) in the U.S., Coffin & Sullivan (2013) in Russia, and Langham et al. (2018) in the 
United Kingdom, with similar incremental cost-effectiveness ratios of $323, $94, and £899 
(about $1,144)/QALY, respectively. All are well within established parameters for  
cost-effective interventions. 
In contrast, an economic model by Cipriano & Zaric (2018) found that a plan to equip all 
Toronto high schools with naloxone kits would not be cost-effective in many scenarios, if 
the frequency of overdose in a Toronto high school was low. This points out the importance 
of distributing naloxone in places and to people at a high level of risk.
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Keane, Egan, & Hawk (2018) used qualitative data and agent-based modeling to simulate  
the effects of different community distribution strategies to high-risk people. Over six 
months, a single community distribution site (i.e., pharmacy, urgent care center, or  
hospital), when giving up to 10 kits per visit to an individual, decreases overdose deaths  
by 8.3% relative to baseline. Adding in secondary distribution (where the individual  
distributes kits to their social network) decreases overdose deaths by 42.5%, more than the 
effect of increasing the number of sites tenfold without secondary distribution.  
Distributing naloxone to an individual at syringe exchange sites decreases deaths by about 
65%, an effect that is unchanged by secondary distribution. 
Pharmacy distribution
Pharmacies are another way to expand naloxone distribution to laypeople. Most states 
have passed laws that allow pharmacists to dispense naloxone under a standing order, 
which does not require a physician’s prescription. At least 23 states have issued statewide 
standing orders by a physician-official, while 24 others allow jurisdictions to pass standing 
order laws. Nine states give pharmacists direct authority to prescribe and sell naloxone to 
the public. In a national evaluation of these laws between 2005 and 2016, Abouk, Pacula, 
& Powell (2019) found that states granting pharmacists direct authority saw a significant 
decrease in overdose deaths, an effect that grew stronger over time. Three years after the 
passage of such laws, overdose deaths fell by an average of 34%, and nonfatal emergency 
department visits increased by 15%. States allowing or issuing standing orders—what the 
investigators termed “indirect authority” for pharmacists—had little effect.
Other studies have assessed the relationship between state laws expanding naloxone  
access and opioid deaths, and reached different conclusions. Concerns have been raised 
that these laws encourage riskier behaviors around opioid use, because rescue is more  
likely. Potentially, this so-called risk compensation could offset or even swamp the reduction 
in deaths due to naloxone’s wider use. Three prior studies have evaluated state laws as a 
package, and two found that the laws were associated with a reduction in opioid deaths in 
the range of 9% (Rees et al., 2017) to 14% (McClellan et al., 2018). However, a recent study 
by Doleac & Mukherjee (2019) found that state laws expanding naloxone distribution were 
associated with more opioid-related emergency department visits and more opioid-related 
theft, with no reduction in opioid-related deaths. The paper created controversy in the  
scientific community as well as in the lay press; while space does not permit a full  
examination of this issue, Frank, Pollack, and Humphreys (2018) capture the debate well.
Recent audit studies in individual states provide insight into how poor implementation 
might limit the effectiveness of state laws in reducing overdose deaths. Puzantian & Gasper 
(2018) conducted a “secret shopper” study of a random sample of all pharmacies in  
California, which has issued a statewide standing order. Just 23.5% of 1,147 pharmacies 
indicated that naloxone was available and could be dispensed without a prescription. 
Similarly, in a secret shopper study by Graves et al. (2018) in Pennsylvania, which also has 
a statewide standing order, 45% of 682 pharmacies said that naloxone was available. Less 
than two-thirds of pharmacy staff members correctly answered questions about the  
standing order, and quotes of out-of-pocket costs ranged from $50 to $4,000. A New York 
Times investigation revealed that of the 720 pharmacies on New York City’s list of  
pharmacies that sell naloxone under the state’s standing order, only 38% had it in stock and 
were willing to dispense it without a prescription. These studies and articles suggest that a 
standing order, in itself, is not enough to overcome supply, knowledge, and cost barriers to 
expanded naloxone availability in pharmacies.
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Over-the-counter (OTC) naloxone
Given that naloxone is non-addictive and safe to use, advocates and policymakers have 
called for it to be sold over the counter. Earlier this year, the FDA took the unprecedented 
step of developing and validating model Drug Facts Labels for naloxone as a nasal spray and 
an autoinjector to encourage companies to enter the OTC market. The model labels can be 
used by sponsors to obtain OTC approval for naloxone.
What might happen to sales and prices if naloxone became available over the counter? In a 
recent study, Murphy and other CHERISH investigators (2019) modeled supply and demand 
factors to predict the effects of converting naloxone to OTC status. 
First, they used a nationwide prescription claims dataset for 2010-2017 (covering 80% of 
retail pharmacies and including out-of-pocket prices) to estimate how sensitive naloxone 
buyers are to price. They found that buyers of naloxone are not very price-sensitive: on 
average, a 10% increase in out-of-pocket price would produce a 2.7% decrease in sales. 
Then they looked to the literature to find estimates on the price and demand effects of  
conversion to OTC status for other drugs. In particular, they focused on nicotine  
replacement therapies as the only other substance use disorder medication that had  
converted from prescription to OTC status. The authors used these estimates in their  
models to predict the change in naloxone sales, given the relative price insensitivity of  
naloxone buyers. If, for example, naloxone out-of-pocket prices increase after conversion  
at the estimated level of nicotine patches (26%) or nicotine gum (33%), the authors predict 
a 71% to 171% increase in naloxone sales.
All else being equal, greater sales of naloxone should increase the opportunities to reverse 
opioid overdoses. But the public health impact of increased sales will depend on how the 
purchasers of OTC naloxone differ from current purchasers in their likelihood of observing 
an overdose and using the product.
Health system distribution: co-prescribing
Another strategy to improve naloxone distribution is to co-prescribe naloxone to patients 
with opioid prescriptions who are at risk for opioid use disorder. The Centers for Disease 
Control and Prevention, the Substance Abuse and Mental Health Services Administration, 
and the American Medical Association all recommend that physicians consider  
co-prescribing naloxone and opioids for patients at high risk, such as those with a history  
of overdose, history of substance use disorder, higher opioid dosages, or concurrent  
benzodiazepine use. Earlier this year, an FDA advisory council recommended labeling  
changes to encourage co-prescribing. A systematic review by Behar, Bagnulo, & Coffin 
(2018) found a growing willingness to prescribe naloxone among primary care providers, 
although co-prescribing remains relatively infrequent, especially in the absence of a formal 
program.
In a recent study of nearly 140,000 commercially insured patients at high risk of opioid 
overdose, Follman, Arora, Lyttle, et al. (2019) found that only 1.5% of high-risk patients, 
including individuals with prior opioid overdose or opioid misuse or dependence, were 
prescribed naloxone, despite numerous interactions with the health care system.
There is little information on the effectiveness and cost-effectiveness of co-prescribing. 
In an observational study in community health centers, Coffin et al. (2016) found that co-
prescribing naloxone to chronic pain patients was associated with fewer opioid-related 
emergency department visits, but did not assess opioid overdose deaths. While improving 
distribution in clinical settings to high-risk patient populations is recommended, further 
studies are needed to understand how to identify the populations who would benefit the 
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Distribution to non-medical first responders
Communities are increasingly training and equipping police and firefighters with naloxone. 
Police, rather than paramedics, are often the first to respond to overdose emergencies, 
particularly in more rural areas. Nationwide, nearly 2,500 law enforcement agencies report 
that their officers carry naloxone, although comprehensive data on the number of rescues 
by police first responders do not exist, and the effectiveness of these programs is unknown. 
Rando et al. (2015) studied opioid overdose deaths before and after a police naloxone 
training program in one Ohio county and found that the program was associated with a 
decrease in opioid overdose mortality in the year after implementation. 
Conclusion
As opioid deaths continue to mount, there is a clear need for strategies that maximize 
the likelihood that naloxone will be on hand at the right time to reverse an overdose. The 
cost-effectiveness of all strategies will depend on reaching high-risk people and their social 
networks, and reducing access and cost barriers to use. Agent-based modeling suggests 
that optimal distribution involves targeting the highest-risk people (for example, in  
syringe-exchange programs) and encouraging secondary distribution among social  
networks in other settings.
This review reveals that OEND programs on a national and local basis are effective and 
cost-effective in reducing opioid overdose deaths in people who use heroin and other  
opioids; that giving direct authority to pharmacists to dispense naloxone is more effective 
than “standing orders” (although the latter has been adopted by far more states); and that 
the effectiveness of co-prescribing remains uncertain. 
Eliminating the need for a prescription holds some promise, and the FDA has actively  
encouraged naloxone manufacturers to apply for OTC status. An economic model predicts 
that naloxone sales could double if sold over the counter, although the ultimate public 
health impact depends on whether these new buyers are likely to observe an overdose. 
Further research is needed to understand the economic impact of the wide variety of OEND 
programs, and whether widespread distribution of naloxone to laypeople is cost-effective. 
While naloxone alone cannot address the magnitude of the opioid crisis, it is one part of a 
multipronged strategy to prevent immediate deaths and link people with opioid use  
disorders to effective treatments. 
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